{"id":8622,"date":"2026-11-15T13:47:29","date_gmt":"2026-11-15T18:47:29","guid":{"rendered":"https:\/\/canasanta.ca\/?p=8622"},"modified":"2026-11-15T13:47:29","modified_gmt":"2026-11-15T18:47:29","slug":"panorama-clinico-terapia-genica-enfermedades-raras-2026","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/","title":{"rendered":"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA"},"content":{"rendered":"<h2 style=\"margin-top:40px;margin-bottom:20px\">PANORAMA Y HALLAZGOS CLAVE<\/h2>\n<p style=\"margin-bottom:26px;line-height:1.75\">Un estudio de alcance global publicado esta semana traza el crecimiento y las limitaciones actuales del desarrollo de la terapia g\u00e9nica para enfermedades raras. Los autores, entre ellos <strong>Renjie Han<\/strong> y colaboradores, compilaron registros p\u00fablicos \u2014incluyendo bases regulatorias y repositorios de ensayos\u2014 para ofrecer una visi\u00f3n *registry-based* del panorama investigador. El informe muestra que la actividad cl\u00ednica se ha acelerado en los \u00faltimos a\u00f1os, aunque predominan fases tempranas y una concentraci\u00f3n geogr\u00e1fica marcada. Estas caracter\u00edsticas condicionan la traducci\u00f3n cl\u00ednica y la equidad de acceso a los futuros tratamientos.<\/p>\n<h2 style=\"margin-top:40px;margin-bottom:20px\">TENDENCIAS EN ENSAYOS Y APROBACIONES<\/h2>\n<p style=\"margin-bottom:26px;line-height:1.75\">Los datos indican que la mayor\u00eda de los estudios son intervinientes y est\u00e1n en fases I o I\/II, con un elevado porcentaje que admite inscripci\u00f3n pedi\u00e1trica. Las indicaciones m\u00e1s frecuentes incluyen hemofilia, distrofia muscular de Duchenne y algunos trastornos retinianos, lo que refleja prioridades cient\u00edficas y comerciales. Al mismo tiempo, el n\u00famero de productos aprobados sigue siendo limitado y concentrado en unas pocas indicaciones, lo que evidencia una brecha entre la investigaci\u00f3n temprana y las aprobaciones regulatorias masivas. El an\u00e1lisis subraya la necesidad de ensayos mejor dise\u00f1ados y de infraestructuras regulatorias que faciliten pasos de fase temprana a aprobaci\u00f3n.<\/p>\n<h2 style=\"margin-top:40px;margin-bottom:20px\">DESAF\u00cdOS T\u00c9CNICOS Y DE SEGURIDAD<\/h2>\n<p style=\"margin-bottom:26px;line-height:1.75\">La heterogeneidad de vectores y estrategias \u2014AAV, lentivirus, edici\u00f3n g\u00e9nica in vivo y enfoques celulares\u2014 plantea retos de seguridad y seguimiento a largo plazo. En los \u00faltimos a\u00f1os se han reportado eventos adversos graves en tratamientos con vectores virales, lo que subraya la importancia de sistemas de farmacovigilancia robustos postaprobaci\u00f3n. Adem\u00e1s, la necesidad de cohortes m\u00e1s amplias y de datos longitudinales complica la evaluaci\u00f3n de eficacia sostenida y de riesgos raros. Los autores proponen est\u00e1ndares de seguimiento y la creaci\u00f3n de registros internacionales para armonizar evidencia y detectar se\u00f1ales de seguridad tempranas.<\/p>\n<figure class=\"alignleft\" style=\"max-width:300px;border:1px solid #ddd;padding:4px\"><img data-recalc-dims=\"1\" decoding=\"async\" src=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-interior.jpg?w=300&#038;quality=82&#038;strip=all&#038;ssl=1\"  alt=\"Ilustraci\u00f3n editorial\"><figcaption style=\"color:#999;font-family:sans-serif\">MAPA DE ENSAYOS GLOBALES \u2014 Distribuci\u00f3n de estudios de terapia g\u00e9nica para enfermedades raras seg\u00fan la base de datos analizada \u2014 Ilustraci\u00f3n CA\u00d1ASANTA<\/figcaption><\/figure>\n<h2 style=\"margin-top:40px;margin-bottom:20px\">IMPLICACIONES PARA PACIENTES Y SISTEMAS DE SALUD<\/h2>\n<p style=\"margin-bottom:26px;line-height:1.75\">La concentraci\u00f3n geogr\u00e1fica de los ensayos sugiere que los pacientes fuera de centros privilegiados podr\u00edan quedar excluidos de acceso temprano a terapias prometedoras. Esa desigualdad tiene repercusiones en la validez externa de los resultados y en la capacidad de los sistemas de salud para planear acceso y financiaci\u00f3n. Los autores recomiendan mecanismos regulatorios que incentiven ensayos multic\u00e9ntricos y alianzas p\u00fablico-privadas para extender la cobertura geogr\u00e1fica. Asimismo, insisten en pol\u00edticas de precios y reembolso que eviten la exclusi\u00f3n por coste una vez que los productos accedan al mercado.<\/p>\n<h2 style=\"margin-top:40px;margin-bottom:20px\">RUMBO A UNA INVESTIGACI\u00d3N M\u00c1S S\u00d3LIDA<\/h2>\n<p style=\"margin-bottom:26px;line-height:1.75\">El estudio concluye con propuestas concretas: estandarizar definiciones de resultados, aumentar la transparencia de datos y facilitar el acceso a repositorios de ensayos. Tambi\u00e9n aboga por mayor participaci\u00f3n internacional en el dise\u00f1o de ensayos para enfermedades poco frecuentes y por plataformas que permitan compartir datos de seguridad en tiempo real. Si se adoptan esas medidas, la comunidad cient\u00edfica y los reguladores podr\u00e1n acelerar la validaci\u00f3n de terapias g\u00e9nicas eficaces y seguras para grupos de pacientes que hoy carecen de opciones.<\/p>","protected":false},"excerpt":{"rendered":"<p>Un estudio reciente traza crecimiento, limitaciones y propuestas para la terapia g\u00e9nica en enfermedades raras, con foco en seguridad y acceso.<\/p>","protected":false},"author":284226809,"featured_media":8620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33205457],"tags":[33205481,33205783,33205887],"class_list":["post-8622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","tag-ciencia","tag-estados-unidos","tag-salud"],"acf":{"introduccion":"","fuentes_y_referencias":"<p style=\"margin-bottom:26px;line-height:1.75\">Fuentes primarias y verificaci\u00f3n: <a href=\"https:\/\/www.nature.com\/articles\/s41434-026-00658-6\">Han et al., \"Clinical landscape of gene therapy for rare diseases\" (Gene Therapy, 13 Nov 2026)<\/a>. Datos complementarios y registros citados por los autores: <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products\">FDA \u2014 Approved Cellular and Gene Therapy Products<\/a>, <a href=\"https:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/a> y <a href=\"https:\/\/www.orpha.net\">Orphanet<\/a>. Se consultaron las fuentes el 15 de noviembre de 2026 para corroborar cifras y metodolog\u00eda.<\/p>","autor":748},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Panorama cl\u00ednico: terapia g\u00e9nica en enfermedades raras<\/title>\n<meta name=\"description\" content=\"An\u00e1lisis del nuevo estudio sobre la expansi\u00f3n y l\u00edmites de la terapia g\u00e9nica en enfermedades raras: fases tempranas, concentraci\u00f3n geogr\u00e1fica y retos regulatorios.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/daily\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA\" \/>\n<meta property=\"og:description\" content=\"An\u00e1lisis del nuevo estudio sobre la expansi\u00f3n y l\u00edmites de la terapia g\u00e9nica en enfermedades raras: fases tempranas, concentraci\u00f3n geogr\u00e1fica y retos regulatorios.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/daily\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-15T18:47:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ca\u00f1asanta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ca\u00f1asanta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/\"},\"author\":{\"name\":\"Ca\u00f1asanta\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA\",\"datePublished\":\"2026-11-15T18:47:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1\",\"keywords\":[\"ciencia\",\"Estados Unidos\",\"salud\"],\"articleSection\":[\"AL D\u00cdA!\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/\",\"name\":\"Panorama cl\u00ednico: terapia g\u00e9nica en enfermedades raras\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-11-15T18:47:29+00:00\",\"description\":\"An\u00e1lisis del nuevo estudio sobre la expansi\u00f3n y l\u00edmites de la terapia g\u00e9nica en enfermedades raras: fases tempranas, concentraci\u00f3n geogr\u00e1fica y retos regulatorios.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1\",\"width\":1536,\"height\":1024,\"caption\":\"Investigadores en un laboratorio revisando datos de ensayos; imagen conceptual que acompa\u00f1a el an\u00e1lisis editorial. \u2014 Ilustraci\u00f3n CA\u00d1ASANTA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/al-dia\\\/panorama-clinico-terapia-genica-enfermedades-raras-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AL D\u00cdA!\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/category\\\/al-dia\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"width\":1500,\"height\":500,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Ca\u00f1asanta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Ca\u00f1asanta\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Panorama cl\u00ednico: terapia g\u00e9nica en enfermedades raras","description":"An\u00e1lisis del nuevo estudio sobre la expansi\u00f3n y l\u00edmites de la terapia g\u00e9nica en enfermedades raras: fases tempranas, concentraci\u00f3n geogr\u00e1fica y retos regulatorios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/daily\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/","og_locale":"en_US","og_type":"article","og_title":"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA","og_description":"An\u00e1lisis del nuevo estudio sobre la expansi\u00f3n y l\u00edmites de la terapia g\u00e9nica en enfermedades raras: fases tempranas, concentraci\u00f3n geogr\u00e1fica y retos regulatorios.","og_url":"https:\/\/canasanta.ca\/en\/daily\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-11-15T18:47:29+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Ca\u00f1asanta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ca\u00f1asanta","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/"},"author":{"name":"Ca\u00f1asanta","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA","datePublished":"2026-11-15T18:47:29+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1","keywords":["ciencia","Estados Unidos","salud"],"articleSection":["AL D\u00cdA!"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/","url":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/","name":"Panorama cl\u00ednico: terapia g\u00e9nica en enfermedades raras","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1","datePublished":"2026-11-15T18:47:29+00:00","description":"An\u00e1lisis del nuevo estudio sobre la expansi\u00f3n y l\u00edmites de la terapia g\u00e9nica en enfermedades raras: fases tempranas, concentraci\u00f3n geogr\u00e1fica y retos regulatorios.","breadcrumb":{"@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1","width":1536,"height":1024,"caption":"Investigadores en un laboratorio revisando datos de ensayos; imagen conceptual que acompa\u00f1a el an\u00e1lisis editorial. \u2014 Ilustraci\u00f3n CA\u00d1ASANTA"},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/al-dia\/panorama-clinico-terapia-genica-enfermedades-raras-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"AL D\u00cdA!","item":"https:\/\/canasanta.ca\/category\/al-dia\/"},{"@type":"ListItem","position":3,"name":"PANORAMA CL\u00cdNICO DE LA TERAPIA G\u00c9NICA"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","width":1500,"height":500,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Ca\u00f1asanta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Ca\u00f1asanta"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-2f4","jetpack-related-posts":[{"id":8424,"url":"https:\/\/canasanta.ca\/en\/salud\/medicina\/nueva-esperanza-contra-el-parkinson\/","url_meta":{"origin":8622,"position":0},"title":"NUEVA ESPERANZA CONTRA EL P\u00c1RKINSON","author":"Ca\u00f1asanta","date":"November 14, 2026","format":false,"excerpt":"UN PROGRESO EN CELULAS Y TERAPIAS QUE REAVIVA LA ESPERANZA En las \u00faltimas semanas la comunidad cient\u00edfica ha publicado una serie de resultados y actualizaciones que apuntan a avances reales en tratamientos experimentales para la enfermedad de Parkinson. Grupos acad\u00e9micos y empresas biotecnol\u00f3gicas han informado sobre datos precl\u00ednicos y de\u2026","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Ilustraci\u00f3n editorial: NUEVA ESPERANZA CONTRA EL P\u00c1RKINSON","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/sasineprocel-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/sasineprocel-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/sasineprocel-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/sasineprocel-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/sasineprocel-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":6449,"url":"https:\/\/canasanta.ca\/en\/al-dia\/ondas-de-sonido-abren-una-nueva-via-contra-el-cancer-cerebral\/","url_meta":{"origin":8622,"position":1},"title":"ONDAS DE SONIDO ABREN UNA NUEVA V\u00cdA CONTRA EL C\u00c1NCER CEREBRAL","author":"Ca\u00f1asanta","date":"November 1, 2026","format":false,"excerpt":"Una tecnolog\u00eda capaz de abrir temporalmente la barrera que protege al cerebro est\u00e1 mostrando una nueva forma de atacar uno de los c\u00e1nceres m\u00e1s dif\u00edciles de tratar. Investigadores de UVA Health trabajan con ultrasonido focalizado, microburbujas y terapias dirigidas para conseguir que medicamentos y c\u00e9lulas inmunitarias lleguen hasta tumores cerebrales\u2026","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Equipo de ultrasonido focalizado utilizado en investigaci\u00f3n m\u00e9dica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Ultrasonido-focalizado-%E2%80%94-investigacion-medica.jpg?fit=1200%2C797&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Ultrasonido-focalizado-%E2%80%94-investigacion-medica.jpg?fit=1200%2C797&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Ultrasonido-focalizado-%E2%80%94-investigacion-medica.jpg?fit=1200%2C797&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Ultrasonido-focalizado-%E2%80%94-investigacion-medica.jpg?fit=1200%2C797&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Ultrasonido-focalizado-%E2%80%94-investigacion-medica.jpg?fit=1200%2C797&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4330,"url":"https:\/\/canasanta.ca\/en\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","url_meta":{"origin":8622,"position":2},"title":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa","author":"Ca\u00f1asanta","date":"October 19, 2026","format":false,"excerpt":"Emvistegrast, una terapia oral experimental de Gilead, alcanz\u00f3 respuesta cl\u00ednica en el 66% de los pacientes con colitis ulcerosa moderada o grave frente al 37% con placebo en un ensayo de fase 2.","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Medicamentos en una investigaci\u00f3n cl\u00ednica sobre colitis ulcerosa","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4199,"url":"https:\/\/canasanta.ca\/en\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","url_meta":{"origin":8622,"position":3},"title":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo","author":"Ca\u00f1asanta","date":"October 22, 2026","format":false,"excerpt":"\u00a0\u00a0Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de\u2026","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"M\u00e9dico conversa con una paciente hospitalizada, imagen editorial para informaci\u00f3n sobre colitis ulcerosa","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":8471,"url":"https:\/\/canasanta.ca\/en\/al-dia\/gazyva-para-nefropatia-membranosa\/","url_meta":{"origin":8622,"position":4},"title":"GAZYVA PARA NEFROPAT\u00cdA MEMBRANOSA","author":"Ca\u00f1asanta","date":"November 15, 2026","format":false,"excerpt":"La FDA aprob\u00f3 Gazyva (obinutuzumab) para tratar la nefropat\u00eda membranosa primaria tras los resultados del ensayo MAJESTY; primera terapia dirigida para esta enfermedad.","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Ilustraci\u00f3n editorial: GAZYVA PARA NEFROPAT\u00cdA MEMBRANOSA","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Gazyva-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Gazyva-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Gazyva-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Gazyva-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Gazyva-portada.jpg?fit=1200%2C800&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5165,"url":"https:\/\/canasanta.ca\/en\/salud\/vacuna-arnm-reduce-42-riesgo-recaida-melanoma\/","url_meta":{"origin":8622,"position":5},"title":"UNA VACUNA DE ARNm REDUCE UN 42% EL RIESGO DE RECA\u00cdDA DEL MELANOMA","author":"Ca\u00f1asanta","date":"October 23, 2026","format":false,"excerpt":"Una vacuna personalizada de ARNm de Moderna y Merck, combinada con Keytruda, redujo un 42% el riesgo de reca\u00edda o muerte por melanoma en un ensayo de fase 3.","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Investigaci\u00f3n de una vacuna personalizada contra el c\u00e1ncer en laboratorio","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/panorama-clinico-terapia-genica-raras-portada.jpg?fit=1536%2C1024&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/8622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=8622"}],"version-history":[{"count":1,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/8622\/revisions"}],"predecessor-version":[{"id":8623,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/8622\/revisions\/8623"}],"acf:post":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/autor\/748"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/8620"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=8622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=8622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=8622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}